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Abstract: Antimalarial drug discovery has historically benefited from the whole-cell (phenotypic) screening approach to 
identify lead molecules in the search for new drugs. However over the past two decades there has been a shift in the 
pharmaceutical industry to move away from whole-cell screening to target-based approaches. As part of a Wellcome Trust 
and Medicines for Malaria Venture (MMV) funded consortium to discover new blood-stage antimalarials, we used both 
approaches to identify new antimalarial chemotypes, two of which have progressed beyond the lead optimization phase 
and display excellent in vivo efficacy in mice. These two advanced series were identified through a cell-based optimiza-
tion devoid of target information and in this review we summarize the advantages of this approach versus a target-based 
optimization. Although the each lead optimization required slightly different medicinal chemistry strategies, we observed 
some common issues across the different the scaffolds which could be applied to other cell based lead optimization pro-
grams. 
Keywords: Lead-optimization, malaria, whole-cell screening, spiroindolones, imidazolopiperazines. 
INTRODUCTION 
  The current arsenal of antimalarials represents drugs that 
are derived from both target-based and whole-cell ap-
proaches, such as dihydrofolate reductase inhibition (DHFR) 
and artemisinin, respectively. Target based approaches start 
with identification of an essential enzyme or pathway, ide-
ally specific to the parasite. After the development of an in 
vitro biochemical assay, an HTS (high-throughput screen) 
can be executed to identify hit compounds. Subsequent 
screening on related human targets can be employed to de-
termine selectivity. Although the advantage is that a selec-
tive compound can mitigate potential host toxicity, the real-
ity is that selective compounds are rare in anti-infectives due 
to conserved target homology, target essentiality, and com-
pound permeability among others. Moreover it can be diffi-
cult to predict the required selectivity index for low toxicity 
required for safety in man. Another common outcome often 
encountered in the early optimization in this approach is an 
in vitro/in vivo disconnect where excellent potency on the 
target does not translate to similar cellular activity or in vivo 
efficacy. More recently, the paucity of new drugs acting on 
“essential” targets has lead to a shift back to the traditional 
phenotypic screening approach. The advantage of this 
whole-cell screening approach is that although the mecha-
nism of action is unknown, compounds identified from the 
screen can at least be deemed cidal and permeable. Recent 
reports of high throughput screening of chemical libraries on 
plasmodium have identified a number of new chemical enti-
ties many without a known mechanism of action (MOA)   
[1, 2, 14]. The lack of an established MOA, often 
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considered a deficiency, has now become an opportunity 
with the advent of genomic techniques that can be used to 
identify new targets by using optimized compounds as 
probes [3]. The disadvantage of this approach however, is 
that the activity can also be the result of multiple pathways 
being targeted leading to very poor or narrow structure activ-
ity relationships (SAR) during the lead optimization phase 
(Table 1). 
  A part of a search for new antimalarials we leveraged 
both approaches to identify new leads. Herein we summarize 
our efforts to date and conclude that although target-based 
approaches can lead to promising preclinical candidates, the 
whole-cell screening of high quality chemical libraries with 
support of early in vitro and in vivo PK profiling can identify 
a diverse range of active scaffolds resulting in shorter lead 
optimization timelines. 
THE TARGET BASED APPROACH 
Diaminoquinazolines for PfDHFR 
 PfDHFR is one of the few clinically validated targets in 
malaria and drugs such as pyrimethamine and cycloguanil 
have proven to be highly effective treatments in the antima-
larial drug arsenal since their introduction. However after 
decades of use, widespread resistance has made these agents 
largely ineffective in endemic areas. The main driver of re-
sistance is the result of multiple mutations in the enzymes' 
active site that effectively prohibit binding of the drug [4]. 
To identify new inhibitors with activity on PfDHFR resistant 
strains, we profiled a known antifolate QN254 (1) which 
displayed equal potency on both wild type PfDHFR and the 
highly pyrimethamine resistant P. falciparum V1S strain 
(Table 2) [5]. Activity on the enzyme also translated well to 
cellular potency on wild type P. falciparum in vitro (EC50 = 
9 nM).  
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  In addition, QN254 exhibited favorable oral pharmacoki-
netic properties in rodents and good efficacy against Plas-
modium berghei in the murine model (Table 3). Excellent in 
vivo oral activity (>99.99% reduction in parasitemia) was 
observed as low as 30 mg/kg with the average mouse sur-
vival prolongation out to 28.4 days. However at higher doses 
QN254 exhibited dose-limiting toxicity and six out of ten 
treated mice died around day ten despite being parasite free; 
the four surviving were cured and parasite free at day 30. We 
attributed this toxicity to activity on the closely related host 
DHFR enzyme. In humans, QN254 displays a 26-fold de-
crease in binding affinity on human versus PfDHFR and has 
the lowest Ki ratio when compared to cycloguanil and 
pyrimethamine. This was later confirmed in a 2-week rat 
toxicology study where QN254 was not tolerated upon re-
peated oral administration of greater than 50 mg/kg. Histopa-
thological analysis revealed significant gastrointestinal and 
bone marrow toxicity. This type of toxicity on proliferative 
cells is consistent with on-target effects of sustained DHFR 
inhibition and underscores the importance of enzyme selec-
tivity towards establishing an adequate therapeutic index [6, 
7]. 
  Despite the fact that the in vitro selectivity is known for 
cycloguanil and pyrimethamine and that they are well toler-
ated drugs, it remain unclear what the true selectivity index 
would be for safety with the next generation anti-folates. 
Purines for PfCDPK1 
 In  P. falciparum, calcium-dependent protein kinase 1 
(PfCDPK1) is expressed during schizogony in the blood and 
sporozoite stages and is ultimately required for parasite inva-
sion of host cells, parasite motility, and potentially cytokine-
sis [8]. We identified a series of purine-based, ATP competi-
tive kinase inhibitors from a target-based screen of approxi-
mately 20,000 compounds on recombinant PfCDPK1 [9]. Of 
the most promising hits, the 2,6,9-trisubstitutes purines made 
up the largest class of compounds coming out of the screen 
and were therefore chosen as a lead series for chemical op-
timization. The main challenge for this series proved to be 
obtaining an interpretable correlation between enzyme inhi-
bition and cell-based activity.  
  Within the hit series, compound 2 (purfalcamine) was 
found to have favorable potency in in vitro biochemical as-
says, whole cell proliferation and in vivo parasitemia sup-
pression, suggesting that the compound may be acting on 
PfCDPK1 within the parasite to exert these effects. Although 
other chemical modifications on the purine ring were incor-
porated during the optimization, substitutions on the N-9 
phenyl generally included the most potent enzyme inhibitors 
(Table 4). m-Fluoro- (2) and the carboxy substituted deriva-
tives 6 and 7 proved to be the most optimal substitutions and 
the best enzyme inhibitors, however improving enzyme ac-
tivity did not lead to improved cellular activity. For example 
Table 1.  The General Sequence of Two Approaches Used to Develop New Antimalarial Candidates 
Target-based Approach  Cell-based Approach 
•  Target identification from ge-
nomic  data of the parasite 
•  Genetic validation of the molecu-
lar target 
•  Target expression, assay devel-
opment 
•  High-throughput screening for hits 
against the target 
•  Lead optimization of hits 
Pros: Known mechanism of action; 
amenable to structure-based lead 
optimization 
 
Cons: Protein expression and assay 
development can be challenging; 
good inhibitor does not mean good 
drug 
•  Identify libraries or classes of 
molecules with potential bio-
logical activity on the parasite 
•  High-throughput screening for 
hits against on the whole para-
site 
•  Lead optimization of hits 
Pros: Active on plasmodium 
(cell penetration); genomic tools 
can lead to the identification of 
new targets in parallel 
 
Cons: Mechanism of action 
unknown; lead optimization can 
be challenging  (presence of 
multiple targets) 
 
Table 2.  Selectivity and Binding of QN254 on PfDHFR and hDHFR 
Ki (nM)  Ki Ratio 
Compound 
WT-PfDHFR
a QM-PfDHFR
b  hDHFR
c  h/Pf-DHFR 
Cycloguanil  1.51 ± 0.1  454 ± 38  55.6 ± 7.8  37 
Pyrimethamine  0.59 ± 0.05  385 ± 163  30.8 ±1.4  52 
QN254  0.39 ± 0.05  0.58 ± 0.06  10.2 ± 0.6  26 
a wild type PfDHFR, 
b quadruple mutant PfDHFR, 
c human DHFR. 
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despite a greater than 200-fold improvement in enzyme po-
tency (2 vs. 3), the cellular activity was similar. This may 
suggest that cell permeability was reduced in compound 2 
relative to compound 3 or that there were other cellular tar-
gets present with compound 3. Poor compound permeability 
might also explain the complete loss of activity at the cellu-
lar level for carboxy derivatives 6 and 7. The overall SAR 
we observed for this series were typical of compounds 4 and 
5 where poor enzyme activity and moderate cellular potency 
were observed. 
  We were ultimately unable to break the 10 nM barrier for 
enzymatic activity or completely rule out off-target activity 
on other intracellular targets since alternate drivers of in vitro 
potency have been previously described for other purine 
templates [10]. We interpreted the poor kinase selectivity for 
PfCDPK1 over human kinases to rationalize the moderate 
cytotoxicity observed. The EC50 value for compound 2 on P. 
falciparum was 230 nM, giving a therapeutic window rang-
ing from 23-fold to 36-fold on mammalian cell lines (EC50s 
for CHO = 12.3 μM, HEp2 = 7.2 μM, HeLa = 7.0 μM, and 
Huh7 = 5.5 μM). Based on this we surmised that increasing 
enzyme activity, without being able to address selectivity 
would further reduce the safety index. In addition to the lack 
of kinase selectivity, the series as a whole displayed poor 
physicochemical properties making it difficult to improve 
the pharmacokinetic (PK) properties of the lead compound 
towards an acceptable oral bioavailability required for an 
anti-malarial drug [11]. 
  Our experience and the experiences of others with target 
based lead optimization does not preclude this approach 
[12]. Successes with PfDHFR and PfDHPS have made a 
profound impact on malaria chemotherapy and more recently 
triazolopyrimidines acting on P. falciparum dihydroorotate 
dehydrogenase (PfDHODH) are currently in preclinical de-
velopment towards proof of concept in man [13]. 
  Any chemical series acting on a parasite target needs to 
display SAR which reflects not only potent enzyme and cel-
lular activity but also selectivity towards the host enzyme, if 
present. As an excellent safety and tolerability profile are 
critical for development of next generation antimalarials, 
achieving optimal enzyme selectivity early will help mitigate 
potential adverse effects. Given that we were unable to 
achieve whole-cell activity and/or selectivity in the above 
chemical series, we directed our efforts towards the histori-
cally more successful cell-based approach. When coupled 
with a novel whole-cell HTS of large compound libraries, we 
were able to identify several new chemotypes for medicinal 
chemistry optimization. 
THE WHOLE-CELL BASED APPROACH 
  We screened both our in-house compound collection 
(~2.3M compounds) and natural products library (12,000 
compounds) using a cell based Plasmodium falciparum pro-
liferation assay [14]. This screen provided data on a large 
number of chemically diverse anti-malarial compounds. 
These nearly 5700 hits have been deposited into the public 
EBI database by GNF/Novartis [15]. A number of these hits 
originated from kinase-directed libraries and many of which 
are pan-kinase inhibitors. De-convoluting and eliminating 
inherent kinase activity with many of these scaffolds while 
maintaining cellular potency was the first step in the hit-to-
lead phase for these particular chemotypes. What follows is a 
summary of the chemical optimization of some kinase-like 
and non-kinase scaffolds which came out of the whole-cell 
screening effort. 
BENZAMIDES 
  The significant disconnect from enzyme to cellular po-
tency with broad-kinase based scaffolds (such as PfCDPK1 
described above) led us to ask a different question: Can cel-
lular potency, namely antimalarial activity, be disconnected 
from the pharmacophore responsible for kinase activity? 
Eliminating the kinase pharmacophore early on in lead opti-
mization would also reduce molecular weight, improve 
ligand efficiency, and potentially reduce off-target toxicity 
[16, 17]. 
 Compound  8, originally designed as a pan-kinase Bcr-
Abl inhibitor, displays moderate activity against the chloro-
quine sensitive 3D7 strain of P. falciparum Fig. (1) [18]. A 
scan of solubilizing groups quickly identified 9 with nearly a 
three fold improved cellular potency. Small changes on the 
western phenyl ring were also tolerated and lead to an equi-
potent compound (10). More importantly this change led to a 
complete loss of human kinase activity as measured in a 
Ba/F3 cell line RTK panel [19]. From this observation we 
concluded that the pharmacophore responsible for kinase 
activity might not be essential for anti-malarial activity, and 
thus removing this moiety from the scaffold could represent 
the minimum pharmacophore [20]. As expected the loss of 
activity on human kinases also resulted in a better safety 
profile of the series on various mammalian cell lines (CC50s 
> 10 μM). This reinforced our conclusion that the kinase-
binding functionality in the purines for PfCDPK1 was likely 
driving the inherent cell toxicity observed for that series. 
 
 
Table 3.  Antimalarial Activity of QN254 in the P. berghei Murine Model
a 
Dosing Regimen  Parasitemia Reduction (%)  Average Survival (days)  Cure Rate (%)  Toxicity Rate (%) 
3 x 30  > 99.99  28.4  80  0 
3 x 60  > 99.99  Not available  60  40
b 
3 x 100  > 99.99  Not available  20  80
b 
a Percent inhibition of parasitemia compared to untreated controls. The mean survival of control animals was 5.6 to 6.2 days; 
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Table 4.  Activity of Purines on PfCDPK1 and P. falciparum 
N
N N
N
HN
O
N
N
H R
H2N
9
 
Compound R  PfCDPK1 IC50 (nM)
a  P. falciparum  3D7 EC50 (nM)
a 
2  F
 
17 230 
3 
O Ph
 
4040 312 
4 
O
O
 
342 400 
5 
O
 
240 535 
6  COOH
 
71 >  10,000 
7 
COOH
 
28 >  10,000 
a Values are mean of two experiments. Each assay plate has mefloquine, sulfadoxine and artemisinin as internal standards. The EC50 values for standard compounds match literature 
values. 
 
  During the optimization of the benzamide series, we also 
observed a difference in activity between the chloroquine 
sensitive 3D7 strain and the multi-drug resistant W2 strain. 
The piperidinyl-pyrrolidine functionality on compound 11 
displayed the largest shift in potency between 3D7 and W2 
strains (nearly six-fold), however we observed that a minute 
structural change from the piperidinyl-pyrrolidine system to 
the bis-piperidine system (12-15) improved activity on the 
W2 strain across several compounds (Table 2). Unfortu-
nately we were unable to further exploit the incremental ac-
tivity gains of the bis-piperidines and compounds remained 
two- to four-fold less active on drug resistant strains. Moreo-
ver when compound 14 was screened against fifteen differ-
ent P. falciparum wild type and drug resistant strains, the in 
vitro EC50s hovered between 100-300 nM. Based on this and 
compared to known antimalarials, we predicted this series 
lacked the in vitro potency required for in vivo efficacy. 
  In addition to the eastern part of the molecule there was a 
significant effort to optimize the central CF3-phenyl and 
western benzamide moieties. Replacement of either central 
phenyl ring with other heterocycles or attempts to replace the 
amide bond (e.g. sulfonamide and urea linkages) consistently 
resulted in a loss of in vitro potency. Overall the benzamide 
series was unable to achieve the low nanomolar potencies 
required for blood-stage efficacy and when combined with Lessons Learned in Modern Target-based and Whole-Cell Lead Optimization  Current Topics in Medicinal Chemistry, 2012, Vol. 12, No. 5    477 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. (1). Substituted benzamides derived from a kinase pharmacophore. 
 
Table 5.  The Activity of Piperidyl Benzamides on Drug Resistant Strains 
CF3
H
N
O
R1
R2
 
Compound R
1 R
2 
P. falciparum 
3D7 EC50 (μM)
a 
P. falciparum 
W2 EC50 (μM)
a 
11 Cl 
N
N
 
0.134 ± 0.056  0.888 ± 0.112 
12 Cl 
N
N
 
0.097 ± 0.018  0.276 ± 0.014  
13 CF3 
N
N
 
0.149 0.299 
14 Cl 
N
N
 
0.140 0.323 
15 CF3 
N
N
 
0.058 0.211 
a Values are mean of two experiments. Each assay plate has mefloquine, sulfadoxine and artemisinin as internal standards. The EC50 values for standard compounds match literature values. 
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the narrow SAR we found it difficult to progress the com-
pounds forward. Despite this we concluded that hit com-
pounds representative of kinase inhibitors can be useful start-
ing points for lead optimization providing that the intrinsic 
kinase activity can be separated from cellular activity early 
on. 
IMIDAZOLOPYRIMIDINES 
  The imidazolopyrimidines were another class of anti-
malarial hits previous optimized from a human kinase pro-
gram. The hit compound (16) possessed moderate activity on 
the 3D7 parasite strain and did not exhibit significant activity 
against a panel of 40 mammalian kinases, which suggested it 
was not a pan-kinase inhibitor [21]. The primary liability of 
compound 16 however was the low aqueous solubility (36 
μM at pH 6.8) and likely driven by the high logD of the 
compound Fig. (2). We primarily sought to address this by 
the introduction of hydrophilic or ionizable groups onto the 
scaffold. A scan of the optimal substitution sites on the 
molecule identified C-2 on the central pyrimidine as the best 
position. To further explore this site we generated a focused  
library which identified the N-methylpiperidine derivative 
(17), which displayed an EC50 of 34 nM on 3D7. Compound 
17 was also evaluated against a panel of fifteen drug resistant 
strains of P. falciparum. EC50 values across all strains were 
lower than 140 nM, many of which were below 100 nM sug-
gesting that the compound might be a good lead to address 
drug resistance. 
  The incorporation of the basic functionality on the central 
ring in close proximity to the presumed kinase binding 
pharmacophore also maintained a clean human kinase profile 
when tested on 190 kinases in both biochemical and cellular 
assay formats. Unfortunately despite the greater than 10-fold 
improvement in potency and the addition of an ionizable 
group, both the aqueous solubility and the clogD were essen-
tially unimproved in 17 over the hit compound and also in-
troduced a potential hERG channel blocker pharmacophore 
by incorporation of a basic/lipophilic group [22]. The fact 
that we were unable to improve physiochemical properties 
and in vitro potency in the same molecule from the hit, we 
decided to investigate other scaffolds. 
IMIDAZOLOPIPERAZINES 
  The imidazolopiperazines represent the latest scaffold we 
have optimized from the whole-cell screen which resulted in 
the identification of a new chemotype with promising blood-
stage activity [23]. Imidazolopiperazine hits from the screen 
(18a-c) represented an attractive series displaying favorable 
potency on both drug-susceptible and -resistant strains, while 
maintaining good selectivity Huh7 cells. The selectivity 
window of cytotoxicity was markedly better than those of 
the kinase directed scaffolds described above. Compound 
18a displayed excellent aqueous solubility (>175 μM at pH 
6.8) and was clean on a panel of cytochrome P450 isoforms 
(IC50 >10 μM). Early issues associated with the scaffold in-
cluded metabolic instability and a slight hERG signal in a 
binding assay (IC50 = 19 μM). 
  There were several key concepts that aided the progres-
sion of this series outside of the normal broad-based SAR to 
improve potency. First, in the early SAR development we 
identified potential metabolic liabilities on the scaffold (in 
silico) and quickly moved to address them without always 
waiting for microsomal stability data. This type of intuitive 
approach allowed us to replace the methylene dioxyphenyl 
group which was identified to be prone to aromatic oxidation 
and dealkylation in other chemical series [24]. The unsubsti-
tuted phenyl ring at the 2-position of the imidazolopiperazine 
was also identified as another potential area of metabolic 
oxidation and was modified very early by the introduction of 
a fluorine atom at the para-position Fig. (3).  
  The early toxicity profiling also identified a potential 
hERG liability which we associated with the primary amine 
of the glycine moiety. A significant effort was spent on un-
derstanding the SAR of the hERG activity and differentiating 
it from in vitro potency. As the terminal amine was required 
for both potency and favorable PK properties, we found that 
original glycine turned out to be the optimal substituent in 
terms of lower hERG activity. In addition to improving po-
tency and understanding the SAR of the hit, we extensively 
profiled early derivatives in a number of in vitro and in vivo 
PK assays including snapshot PK experiments in mice as an 
early assessment of oral exposure [25].  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. (2). Optimization path for imidazolopyrimidine kinase library hit. 
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Table 6.  The Activity of Imidazolopiperazine Hits 
N
N
N
NH
O
O
R1
18 (a-c)  
Compound R
1 
P. falciparum 
3D7 EC50 (nM)
a 
P. falciparum 
W2 EC50 (nM)
a 
Cytotoxicity (μM) 
Huh7
a 
18a Gly  63  97 >  10 
18b (DL)-Phe 235  271  >10 
18c (DL)-Leu 116  119  >10 
a Values are mean of two experiments. 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. (3). Summary of hit to lead for the imidazolopiperazines series. 
 
We also found that an in vitro permeability assay (PAMPA), 
metabolic stability in liver microsomes and mouse snapshot 
oral PK were predictive in helping to understanding efficacy 
in the mouse model. Compounds were prioritized that 
showed good permeability and low clearance in liver micro-
somes. Access to these types of in vitro assays, both within 
industry and academia, can greatly accelerate the drug dis-
covery process. 
 Compounds  19 and 20 were tested in the P. berghei 
mouse model to assess how in vitro activity translated to in 
vivo efficacy (Table 7) [26]. At all dosing regimens both 
compounds showed excellent activity, reducing parasitemia 
by more than 99%. Despite the excellent activity, clear dif-
ferences in the survival of the mice were observed. At a low 
dose of 30 mg/kg, and despite the greater than 99% activity, 
these compounds were unable to prolong mouse survival 
much past the control group. However increasing the dose to 
100 mg/kg or dosing for three consecutive days (3 x 30 
mg/kg) prolonged mice survival for about two weeks. Both 
19 and 20 showed parasitemia reduction activities and sur-
vival prolongation comparable those of chloroquine (CQ) 
and artesunate (AS) at similar doses. 
  The imidazolopiperazines as a class showed a number of 
key differences from the other cellular hits described above. 
Although establishing SAR towards low nanomolar potency 
is critical early on, understanding the drivers of good PK is 
also needed to establish an in vitro/in vivo correlation as 
early as possible. This correlation ultimately provides confi-
dence in the quality of the hit to warrant further develop-
ment. The optimization of 18a from hit to lead (19 and 20) 
provided a basis for a successful lead optimization campaign 
towards a preclinical candidate.  
SPIROINDOLONES 
  Natural products or drugs derived from natural products 
not only represent the mainstay of anti-malarial chemothera-
pies but also the successful implementation of whole-cell 
screening approaches [27]. Based on this premise we 
screened the Novartis natural product library containing both 
pure natural products and natural product-like synthetic 
compounds. The hit compound (21) was identified as a ra-
cemic mixture of unknown configuration and displayed 
moderate potency on both on the drug susceptible NF54 and 
chloroquine-resistant K1 P. falciparum strain Fig. (4) [28]. 
Catechol prone to oxidation,
metabolic liability
Unsubstituted phenyl ring,
metabolic liability
19 R = H
20 R = Cl
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H2N
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N H2N
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The presence of the central spirocenter gave the molecule a 
unique overall shape compared to the achiral, planar hits 
often encountered in HTS screens and distinguished itself 
from some of the other natural product hits which were high 
molecular weight complex structures. The compound dis-
played moderate aqueous solubility (75 μM at pH 6.8) and 
99% permeability in a PAMPA assay. This in vitro PK pro-
file correlated well with a full in vivo PK experiment in 
mouse where a single 25 mg/kg oral dose resulted in a high 
Cmax (1.4 μM), good oral bioavailability (F = 59%), and an 
oral T1/2 of nearly four hours. Compound 21 also had a fa-
vorable early safety profile when screened against a panel of 
mammalian cell lines, hERG, cytochrome P450 isoforms, 
and in a panel of human relevant proteins (IC50s >10-30 
μM). 
  One of our first tasks was to de-convolute the activity of 
the racemate. This was achieved by chiral separation fol-
lowed by an X-ray crystal structure to unambiguously eluci-
date the configuration of both stereocenters. Interestingly we 
also observed a significant difference in the activity of com-
pounds 22 and 23, with only the 1R,3S enantiomer responsi-
ble for biological activity.  
  Based on the favorable physicochemical properties and in 
vivo PK of 21, we elected to evaluate it in the P. berghei 
mouse model. Remarkably, a single oral dose of 100 mg/kg 
resulted in a 96% reduction in parasitemia. Although only a 
slight prolongation in mouse survival over control (seven 
days) was observed at this dose, it was nonetheless an unex-
pected result given the moderate in vitro potency. We sur-
mised that in vivo efficacy might be improved upon increas-
ing the potency of the compound.  
 Differences  in  the  in vitro potency of enantiomers ex-
tended to other properties as well; most notably metabolic 
stability in the presence of liver microsomes. For example 
compound 24 (six membered spiro) displayed improved in 
vitro potency over the hit and moderate clearance in mouse 
and human microsomes (Table 8). However profiling the 
individual enantiomers separately showed that the active 
enantiomer (26) was metabolized much more readily than 
the inactive enantiomer (25). Based on this result our task 
was to combine the low clearance of the inactive enantiomer 
with the potency of the active enantiomer. We identified the 
aromatic portion of the tetrahydro--carboline ring on 26 as 
metabolically susceptible and focused on introducing sub-
stituents to hinder oxidation at these sites.  
  The microsomal clearance assay proved to be predictive 
in assessing the metabolic stability of the spiroindolones; and 
those derivatives which displayed high stability were also 
found to have low clearance in mouse PK experiments. By 
systematic substitutions on the indole moiety of the spiroin-
dolones we found that blocking the C-7 position had the 
most marked effect on increasing the half life in the presence 
of liver microsomes (Table 9). Fortuitously indole substitu-
tions also provided 3-10 fold gains in potency, with the 6,7-
di-substituted derivatives displaying the most additive effects 
(29 and 30). 
  The improvements in the metabolic stability and potency 
of the spiroindolones translated remarkably well to in vivo 
efficacy in the P. berghei infected mouse model and spiroin-
dolones 26, 29, and 30 out performed current antimalarial 
treatments under similar dosing regimens (Table 10). Single 
oral doses of 30 mg/kg showed survival prolongation in mice 
Table 7.  In Vivo Efficacy of Imidazolopiperazine Leads
 a 
1 x 30 mg/kg  1 x 100 mg/kg  3 x 30 mg/kg 
Compound 
Activity (%)  Survival (Days)  Activity (%)  Survival (Days)  Activity (%)  Survival (Days) 
19  99.3  7.7  99.6 13.3 99.9 14.0 
20
b  99.4  7.7  99.4 17.0 99.8 17.7 
CQ 99.7  8.7  >99.9  12  98.6  18.8 
AS  89 7.2 97 6.7 98 7.2 
a average parasitemia reduction; survival of 6-7 days for untreated mice; 7% Tween 80/3% ethanol formulation. 
b 75% PEG300/25%D5W formulation. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. (4). The activity of the spiroindolone hit and its stereoisomers. 
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Table 8.  Differences in Potency between Enantiomers Extended to Metabolic Stability 
Compound 
N
H
NH
N
H O
Cl
 
24 
N
H
NH
N
H O
Cl
 
25 
N
H
NH
N
H O
Cl
 
26 
NF54 EC50 (nM) 27  >5000  9.2 
Liver Microsomes
a CLint
  t1/2 (min) CLint  t1/2 (min) CLint  t1/2 (min) 
Mouse Med  26.5  Low  103  High  1.8 
Human Med  9.9  Low 95  High  1.2 
a intrinsic clearance in liver microsomes; where high clearance corresponds to low stability in the presence of liver enzymes 
 
Table 9.  Additive SAR Simplified the Lead Optimization of the Spiroindolones 
N
H
NH
N
H O
Cl
R1
R2
6
7
 
Compound 
R
1 = F 
R
2 = H 
27 
R
1 = H 
R
2 = F 
28 
R
1 = F 
R
2 = F 
29 
R
1 = F 
R
2 = Cl 
30 (NITD609) 
NF54 EC50 (nM) 3.4  3.5  0.2  0.9 
Liver Microsomes
a CLint
  t1/2 (min) CLint  t1/2 (min) CLint  t1/2 (min) CLint  t1/2 (min) 
Mouse High  4.2  Low  53  Low  49.1  Low  49 
Human  Med  10  Low 53.3 Low 56.4  Low  76 
a intrinsic clearance in liver microsomes; where high clearance corresponds to low stability in the presence of liver enzymes. 
 
greater than controls; out to 10 days to two weeks. Multiple 
daily doses of 3 x 30 mg/kg yielded more striking results 
with mouse survival out to 18.8 and 23.8 days with com-
pounds 26 and 29, respectively. The same dosing regimen 
with 30 prolonged survival out to 29.1 days in a 30 day ex-
periment and single oral dose of 30 at 100 mg/kg completely 
cleared a P. berghei infection in all treated mice [29]. Orally 
administered 30 displayed a long half-life (T1/2 = 10 hours) 
and excellent bioavailability (F =100%) in mice, consistent 
with a low dose, long lasting antimalarial drug. 
 Retrospectively  compound  21 represented a high quality 
hit with favorable physicochemical properties and good oral 
PK properties. The spirocenter imparted a three dimensional-
ity to the overall shape of the molecule which we believe 
gave the molecule good intrinsic solubility not generally 
encountered in highly planar, aromatic compounds. Al-
though part of our natural product collection, 21 is not a 
natural product and instead is fully synthetic [30]. Finally, 
compound  21 also happened to represent the minimum 
pharmacophore of the series. Nearly all of the essential struc-
tural components required for potency in the optimized com-
pound can be found in the hit (e.g. the spirocenter, 3-methyl 
substituent, and the substituted oxindole moiety). We believe 
this is another one of the key reasons we were able to rapidly 
and efficiently optimize the series [28]. 
CONCLUSION 
  There are numerous examples of successful antimalarial 
drugs derived from natural products where the target and 
mode of action was unknown at the time, most notably qui-
nine and artemisinin. During the discovery and development 
of these drugs, the whole-cell approach was the only method 
available to drug discovery. More recently, armed with the 
genome of the most deadly malaria parasite, P. falciparum, 482    Current Topics in Medicinal Chemistry, 2012, Vol. 12, No. 5  Chatterjee and Yeung 
new target based approaches were predicted to provide an 
influx of next generation antimalarials working through new, 
parasite specific targets. Unfortunately this has yet to be real-
ized as many genetically validated targets exist but few have 
been chemically and more importantly, clinically validated. 
  Although target-based approaches in the search for new 
antimalarials remains an active area of research, new chemi-
cal entities from HTS whole-cell screens of large chemical 
libraries are beginning to bolster the antimalarial pipeline at 
a more efficient pace than target-based screening. Cell-based 
screening has provided a large amount of chemical diversity 
but the subsequent triaging and prioritization of compounds 
can be challenging. Compound prioritization should be as-
sessed not only by potency but also by physicochemical 
properties and supported by early in vivo PK experiments. 
By identifying hit scaffolds which have favorable intrinsic 
properties such as good solubility and permeability, or by 
showing that the scaffold can tolerate the introduction of 
new structural elements which impart such favorable proper-
ties, may help simplify the optimization or at a minimum 
serve to reach a no-go decision sooner. 
  Of the scaffolds described above, only the spiroindolones 
and imidazolopiperazines were able to progress past lead 
optimization towards preclinical development. In retrospect 
one crucial aspect that both compound series shared was the 
early establishment of an in vitro/in vivo correlation with 
good physiochemical properties. Another important detail 
was that the original hit or lead compound was very closely 
related to the minimal pharmacophore required for antima-
larial activity and thus required no gross changes, again sim-
plifying the lead optimization. These attributes were clearly 
lacking in the other scaffolds discussed above and required a 
much more lengthy optimization campaign. Hopefully, these 
strategies and lessons learned can assist in optimization of 
the many unexplored hits that are now in the public domain 
for the betterment of malaria patients. 
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